Lixisenatide as add‐on treatment among patients with different β‐cell function levels as assessed by HOMA‐β index
Identifieur interne : 000886 ( Main/Exploration ); précédent : 000885; suivant : 000887Lixisenatide as add‐on treatment among patients with different β‐cell function levels as assessed by HOMA‐β index
Auteurs : Riccardo C. Bonadonna ; Lawrence Blonde ; Mikhail Antsiferov ; Rachele Berria ; Pierre Gourdy ; Mensud Hatunic ; Viswanathan Mohan ; Michael HorowitzSource :
- Diabetes/Metabolism Research and Reviews [ 1520-7552 ] ; 2017.
Abstract
The effect of lixisenatide—a prandial once‐daily glucagon‐like peptide‐1 receptor agonist—on glycaemic control in patients with inadequately controlled type 2 diabetes mellitus (T2DM), stratified by baseline β‐cell function, was assessed.
The 24‐week GetGoal‐M, ‐P and ‐S trials evaluated the efficacy and safety of lixisenatide in combination with oral antidiabetic agents. This post hoc analysis used data from patients receiving lixisenatide in these trials, divided into matched cohorts by propensity scoring, and stratified according to baseline homeostasis model assessment of β‐cell function (HOMA‐β) index levels, high HOMA‐β: > median HOMA‐β (28.49%); low HOMA‐β: ≤ median.
The matched “low” and “high” HOMA‐β index cohorts (N = 546 patients) had comparable baseline parameters. Mean change from baseline in glycated haemoglobin (HbA1c) was −0.85% and −0.94% for low and high HOMA‐β cohorts, respectively (
In patients with T2DM, lixisenatide was associated with reduction in HbA1c and improvements in both FPG and PPG, regardless of β‐cell function, indicating that lixisenatide is effective in reducing hyperglycaemia, even in patients with more advanced stages of T2DM and poor residual β‐cell function.
Url:
DOI: 10.1002/dmrr.2897
PubMed: 28303626
PubMed Central: 5600123
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 002412
- to stream Pmc, to step Curation: 002262
- to stream Pmc, to step Checkpoint: 000220
- to stream PubMed, to step Corpus: 000661
- to stream PubMed, to step Curation: 000659
- to stream PubMed, to step Checkpoint: 000659
- to stream Ncbi, to step Merge: 004484
- to stream Ncbi, to step Curation: 004484
- to stream Ncbi, to step Checkpoint: 004484
- to stream Main, to step Merge: 000881
- to stream Main, to step Curation: 000886
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Lixisenatide as add‐on treatment among patients with different β‐cell function levels as assessed by HOMA‐β index</title><author><name sortKey="Bonadonna, Riccardo C" sort="Bonadonna, Riccardo C" uniqKey="Bonadonna R" first="Riccardo C." last="Bonadonna">Riccardo C. Bonadonna</name><affiliation><nlm:aff id="dmrr2897-aff-0001"></nlm:aff></affiliation></author><author><name sortKey="Blonde, Lawrence" sort="Blonde, Lawrence" uniqKey="Blonde L" first="Lawrence" last="Blonde">Lawrence Blonde</name><affiliation><nlm:aff id="dmrr2897-aff-0002"></nlm:aff></affiliation></author><author><name sortKey="Antsiferov, Mikhail" sort="Antsiferov, Mikhail" uniqKey="Antsiferov M" first="Mikhail" last="Antsiferov">Mikhail Antsiferov</name><affiliation><nlm:aff id="dmrr2897-aff-0003"></nlm:aff></affiliation></author><author><name sortKey="Berria, Rachele" sort="Berria, Rachele" uniqKey="Berria R" first="Rachele" last="Berria">Rachele Berria</name><affiliation><nlm:aff id="dmrr2897-aff-0004"></nlm:aff></affiliation></author><author><name sortKey="Gourdy, Pierre" sort="Gourdy, Pierre" uniqKey="Gourdy P" first="Pierre" last="Gourdy">Pierre Gourdy</name><affiliation><nlm:aff id="dmrr2897-aff-0005"></nlm:aff></affiliation></author><author><name sortKey="Hatunic, Mensud" sort="Hatunic, Mensud" uniqKey="Hatunic M" first="Mensud" last="Hatunic">Mensud Hatunic</name><affiliation><nlm:aff id="dmrr2897-aff-0006"></nlm:aff></affiliation></author><author><name sortKey="Mohan, Viswanathan" sort="Mohan, Viswanathan" uniqKey="Mohan V" first="Viswanathan" last="Mohan">Viswanathan Mohan</name><affiliation><nlm:aff id="dmrr2897-aff-0007"></nlm:aff></affiliation></author><author><name sortKey="Horowitz, Michael" sort="Horowitz, Michael" uniqKey="Horowitz M" first="Michael" last="Horowitz">Michael Horowitz</name><affiliation><nlm:aff id="dmrr2897-aff-0008"></nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">28303626</idno><idno type="pmc">5600123</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5600123</idno><idno type="RBID">PMC:5600123</idno><idno type="doi">10.1002/dmrr.2897</idno><date when="2017">2017</date><idno type="wicri:Area/Pmc/Corpus">002412</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">002412</idno><idno type="wicri:Area/Pmc/Curation">002262</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">002262</idno><idno type="wicri:Area/Pmc/Checkpoint">000220</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000220</idno><idno type="wicri:source">PubMed</idno><idno type="wicri:Area/PubMed/Corpus">000661</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000661</idno><idno type="wicri:Area/PubMed/Curation">000659</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000659</idno><idno type="wicri:Area/PubMed/Checkpoint">000659</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000659</idno><idno type="wicri:Area/Ncbi/Merge">004484</idno><idno type="wicri:Area/Ncbi/Curation">004484</idno><idno type="wicri:Area/Ncbi/Checkpoint">004484</idno><idno type="wicri:doubleKey">1520-7552:2017:Bonadonna R:lixisenatide:as:add</idno><idno type="wicri:Area/Main/Merge">000881</idno><idno type="wicri:Area/Main/Curation">000886</idno><idno type="wicri:Area/Main/Exploration">000886</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Lixisenatide as add‐on treatment among patients with different β‐cell function levels as assessed by HOMA‐β index</title><author><name sortKey="Bonadonna, Riccardo C" sort="Bonadonna, Riccardo C" uniqKey="Bonadonna R" first="Riccardo C." last="Bonadonna">Riccardo C. Bonadonna</name><affiliation><nlm:aff id="dmrr2897-aff-0001"></nlm:aff></affiliation></author><author><name sortKey="Blonde, Lawrence" sort="Blonde, Lawrence" uniqKey="Blonde L" first="Lawrence" last="Blonde">Lawrence Blonde</name><affiliation><nlm:aff id="dmrr2897-aff-0002"></nlm:aff></affiliation></author><author><name sortKey="Antsiferov, Mikhail" sort="Antsiferov, Mikhail" uniqKey="Antsiferov M" first="Mikhail" last="Antsiferov">Mikhail Antsiferov</name><affiliation><nlm:aff id="dmrr2897-aff-0003"></nlm:aff></affiliation></author><author><name sortKey="Berria, Rachele" sort="Berria, Rachele" uniqKey="Berria R" first="Rachele" last="Berria">Rachele Berria</name><affiliation><nlm:aff id="dmrr2897-aff-0004"></nlm:aff></affiliation></author><author><name sortKey="Gourdy, Pierre" sort="Gourdy, Pierre" uniqKey="Gourdy P" first="Pierre" last="Gourdy">Pierre Gourdy</name><affiliation><nlm:aff id="dmrr2897-aff-0005"></nlm:aff></affiliation></author><author><name sortKey="Hatunic, Mensud" sort="Hatunic, Mensud" uniqKey="Hatunic M" first="Mensud" last="Hatunic">Mensud Hatunic</name><affiliation><nlm:aff id="dmrr2897-aff-0006"></nlm:aff></affiliation></author><author><name sortKey="Mohan, Viswanathan" sort="Mohan, Viswanathan" uniqKey="Mohan V" first="Viswanathan" last="Mohan">Viswanathan Mohan</name><affiliation><nlm:aff id="dmrr2897-aff-0007"></nlm:aff></affiliation></author><author><name sortKey="Horowitz, Michael" sort="Horowitz, Michael" uniqKey="Horowitz M" first="Michael" last="Horowitz">Michael Horowitz</name><affiliation><nlm:aff id="dmrr2897-aff-0008"></nlm:aff></affiliation></author></analytic><series><title level="j">Diabetes/Metabolism Research and Reviews</title><idno type="ISSN">1520-7552</idno><idno type="eISSN">1520-7560</idno><imprint><date when="2017">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><title>Abstract</title><sec id="dmrr2897-sec-0001"><title>Background</title><p>The effect of lixisenatide—a prandial once‐daily glucagon‐like peptide‐1 receptor agonist—on glycaemic control in patients with inadequately controlled type 2 diabetes mellitus (T2DM), stratified by baseline β‐cell function, was assessed.</p></sec><sec id="dmrr2897-sec-0002"><title>Methods</title><p>The 24‐week GetGoal‐M, ‐P and ‐S trials evaluated the efficacy and safety of lixisenatide in combination with oral antidiabetic agents. This post hoc analysis used data from patients receiving lixisenatide in these trials, divided into matched cohorts by propensity scoring, and stratified according to baseline homeostasis model assessment of β‐cell function (HOMA‐β) index levels, high HOMA‐β: > median HOMA‐β (28.49%); low HOMA‐β: ≤ median.</p></sec><sec id="dmrr2897-sec-0003"><title>Results</title><p>The matched “low” and “high” HOMA‐β index cohorts (N = 546 patients) had comparable baseline parameters. Mean change from baseline in glycated haemoglobin (HbA<sub>1c</sub>) was −0.85% and −0.94% for low and high HOMA‐β cohorts, respectively (<italic>P</italic> = .2607). Reductions from baseline in fasting plasma glucose (FPG; −0.77 vs −1.04 mmol/L; <italic>P</italic> = .1496) and postprandial plasma glucose (PPG; −5.82 vs −5.61 mmol/L; <italic>P</italic> = .7511) were similar in the low versus high HOMA‐β index cohorts. Reduction in body weight was significantly greater in the low versus high HOMA‐β index cohort (–2.06 vs –1.13 kg, respectively; <italic>P</italic> = .0006).</p></sec><sec id="dmrr2897-sec-0004"><title>Conclusions</title><p>In patients with T2DM, lixisenatide was associated with reduction in HbA<sub>1c</sub> and improvements in both FPG and PPG, regardless of β‐cell function, indicating that lixisenatide is effective in reducing hyperglycaemia, even in patients with more advanced stages of T2DM and poor residual β‐cell function.</p></sec></div></front><back><div1 type="bibliography"><listBibl><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct></listBibl></div1></back></TEI><affiliations><list></list><tree><noCountry><name sortKey="Antsiferov, Mikhail" sort="Antsiferov, Mikhail" uniqKey="Antsiferov M" first="Mikhail" last="Antsiferov">Mikhail Antsiferov</name><name sortKey="Berria, Rachele" sort="Berria, Rachele" uniqKey="Berria R" first="Rachele" last="Berria">Rachele Berria</name><name sortKey="Blonde, Lawrence" sort="Blonde, Lawrence" uniqKey="Blonde L" first="Lawrence" last="Blonde">Lawrence Blonde</name><name sortKey="Bonadonna, Riccardo C" sort="Bonadonna, Riccardo C" uniqKey="Bonadonna R" first="Riccardo C." last="Bonadonna">Riccardo C. Bonadonna</name><name sortKey="Gourdy, Pierre" sort="Gourdy, Pierre" uniqKey="Gourdy P" first="Pierre" last="Gourdy">Pierre Gourdy</name><name sortKey="Hatunic, Mensud" sort="Hatunic, Mensud" uniqKey="Hatunic M" first="Mensud" last="Hatunic">Mensud Hatunic</name><name sortKey="Horowitz, Michael" sort="Horowitz, Michael" uniqKey="Horowitz M" first="Michael" last="Horowitz">Michael Horowitz</name><name sortKey="Mohan, Viswanathan" sort="Mohan, Viswanathan" uniqKey="Mohan V" first="Viswanathan" last="Mohan">Viswanathan Mohan</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000886 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000886 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= PMC:5600123
|texte= Lixisenatide as add‐on treatment among patients with different β‐cell function levels as assessed by HOMA‐β index
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:28303626" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |